Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia

Authors

Russell Schilder, Fox Chase Comprehensive Cancer Center
Arturo Molina, Biogen Idec
Nancy Bartlett, Washington University School of Medicine in St. Louis
Thomas Witzig, Mayo Clinic
Leo Gordon, Northwestern University
James Murray, Anderson Cancer Center
Stewart Spies, Northwestern University
Hua Wang, Biogen Idec
Gregory Wiseman, Mayo Clinic
Christine White, Biogen Idec

Journal

Cancer Biotherapy & Radiopharmaceuticals

Publication Date

2004

Volume

19

Issue

4

Inclusive Pages

478-481

Document Type

Open Access Publication

DOI

10.1089/cbr.2004.19.478

Rights and Permissions

Russell Schilder, Arturo Molina, Nancy Bartlett, Thomas Witzig, Leo Gordon, James Murray, Stewart Spies, Hua Wang, Gregory Wiseman, and Christine White. Cancer Biotherapy & Radiopharmaceuticals. August 2004, 19(4): 478-481. doi:10.1089/cbr.2004.19.478. This is a copy of an article published in Cancer biotherapy & radiopharmaceuticals © 2004 [copyright Mary Ann Liebert, Inc.]; Cancer biotherapy & radiopharmaceuticals is available online at: http://online.liebertpub.com.

Recommended Citation

Schilder, Russell; Molina, Arturo; Bartlett, Nancy; Witzig, Thomas; Gordon, Leo; Murray, James; Spies, Stewart; Wang, Hua; Wiseman, Gregory; and White, Christine, "Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia." Cancer Biotherapy & Radiopharmaceuticals. 19, 4. 478-481. (2004).
https://digitalcommons.wustl.edu/open_access_pubs/3129